Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03137264 · ClinicalTrials.gov registry record
Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 44
- Enrollment target
NCT03137264 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 44 participants.
The verdict
NCT03137264 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 44 participants
- Enrollment target
Study Summary
The study is being done to determine if non-invasive testing (urine and plasma testing) is as effective as tissue testing in identifying epidermal growth factor receptor (EGFR) T790M mutation status. EGFR is a type of protein found on the surface of cells in the body. When this protein is mutated and becomes too active, it can lead to cancer growth. T790M is a mutation that develops in response to treatment of the EGFR mutation. Participating patients will have tumor tissue (via cobas test), as well as 2 plasma samples (via cobas and Guardant360 tests) and 1 urine sample (via Trovera test), tested for EGFR T790M mutation status. If the results of the cobas tissue and/or plasma test show that a patient is T790M positive, they will be treated according to standard of care, which may include treatment with osimertinib. Osimertinib is approved for use in the United States for the treatment of EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).
Interventions
- DRUG Other
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2017-10-24 |
| Est. Completion | 2018-11-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03137264
The ClinicalTrials.gov registry entry for NCT03137264 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Other is the first listed.
NCT03137264 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03137264 about?
NCT03137264 is a clinical study titled "Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients". The study is being done to determine if non-invasive testing (urine and plasma testing) is as effective as tissue testing in identifying epidermal growth factor receptor (EGFR) T790M mutation status. EGFR is a type of protein found on the surface of cells in the body. When this protein is mutated an...
What is the current status of trial NCT03137264?
This trial is currently completed. The enrollment target is 44 participants. The study started on 2017-10-24. Estimated completion is 2018-11-10.
What interventions are being tested in trial NCT03137264?
The interventions under investigation include: Other (DRUG).
Who is sponsoring clinical trial NCT03137264?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.